1. Home
  2. LUNG vs RENE Comparison

LUNG vs RENE Comparison

Compare LUNG & RENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LUNG
  • RENE
  • Stock Information
  • Founded
  • LUNG 1995
  • RENE 2021
  • Country
  • LUNG United States
  • RENE United States
  • Employees
  • LUNG N/A
  • RENE N/A
  • Industry
  • LUNG Industrial Specialties
  • RENE Blank Checks
  • Sector
  • LUNG Health Care
  • RENE Finance
  • Exchange
  • LUNG Nasdaq
  • RENE Nasdaq
  • Market Cap
  • LUNG 248.0M
  • RENE 243.8M
  • IPO Year
  • LUNG 2020
  • RENE 2022
  • Fundamental
  • Price
  • LUNG $6.67
  • RENE $11.50
  • Analyst Decision
  • LUNG Strong Buy
  • RENE
  • Analyst Count
  • LUNG 7
  • RENE 0
  • Target Price
  • LUNG $13.71
  • RENE N/A
  • AVG Volume (30 Days)
  • LUNG 213.2K
  • RENE 42.3K
  • Earning Date
  • LUNG 10-28-2024
  • RENE 01-01-0001
  • Dividend Yield
  • LUNG N/A
  • RENE N/A
  • EPS Growth
  • LUNG N/A
  • RENE N/A
  • EPS
  • LUNG N/A
  • RENE 0.36
  • Revenue
  • LUNG $76,583,000.00
  • RENE N/A
  • Revenue This Year
  • LUNG $22.73
  • RENE N/A
  • Revenue Next Year
  • LUNG $19.02
  • RENE N/A
  • P/E Ratio
  • LUNG N/A
  • RENE $32.09
  • Revenue Growth
  • LUNG 26.26
  • RENE N/A
  • 52 Week Low
  • LUNG $5.46
  • RENE $10.81
  • 52 Week High
  • LUNG $14.84
  • RENE $11.58
  • Technical
  • Relative Strength Index (RSI)
  • LUNG 37.51
  • RENE 85.94
  • Support Level
  • LUNG $6.39
  • RENE $11.40
  • Resistance Level
  • LUNG $7.47
  • RENE $11.48
  • Average True Range (ATR)
  • LUNG 0.36
  • RENE 0.01
  • MACD
  • LUNG -0.20
  • RENE 0.00
  • Stochastic Oscillator
  • LUNG 12.93
  • RENE 100.00

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

About RENE Cartesian Growth Corporation II

Cartesian Growth Corp II is a blank check company.

Share on Social Networks: